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peripheral artery disease
Ryan J. Mays, PhD, MPH,a,b R. Kevin Rogers, MD, MSc,a,c William R. Hiatt, MD,a,c and
Judith G. Regensteiner, PhD,a,b,d Aurora, Colo
Background: Supervised walking programs offered at medical facilities for patients with peripheral artery disease (PAD)
and intermittent claudication (IC), although effective, are often not used due to barriers, including lack of reimbursement
and the need to travel to specialized locations for the training intervention. Walking programs for PAD patients that
occur in community settings, such as those outside of supervised settings, may be a viable treatment option because they
are convenient and potentially bypass the need for supervised walking. This review evaluated the various methods and
outcomes of community walking programs for PAD.
Methods: A literature review using appropriate search terms was conducted within PubMed/MEDLINE and the Cochrane
databases to identify studies in the English language that used community walking programs to treat PAD patients with
IC. Search results were reviewed, and relevant articles were identiﬁed that form the basis of this review. The primary
outcome was peak walking performance on the treadmill.
Results: Ten randomized controlled trials examining peak walking outcomes in 558 PAD patients demonstrated that
supervised exercise programs were more effective than community walking studies that consisted of general recommen-
dations for patients with IC to walk at home. Recent community trials that incorporated more advice and feedback for
PAD patients in general resulted in similar outcomes, with no differences in peak walking time compared with supervised
walking exercise groups.
Conclusions: Unstructured recommendations for patients with symptomatic PAD to exercise in the community are not
efﬁcacious. Community walking programs with more feedback and monitoring offer improvements in walking perfor-
mance for patients with claudication and may bypass some obstacles associated with facility-based exercise
programs. (J Vasc Surg 2013;58:1678-87.)Atherosclerotic peripheral artery disease (PAD) results
from the accumulation of plaque in the arteries of the
periphery and causes intermittent claudication (IC) in
approximately one-third of patients.1 A comprehensive
medical approach to reducing cardiovascular risk is war-
ranted in all PAD patients. In addition, those with IC
should receive therapy focused on improving walking
ability, functional capacity, and patient-reported outcomes.
Supervised walking exercise is an effective therapy for treat-
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8improving outcomes. These programs are associated with
a number of implementation barriers, however, such as
lack of reimbursement and the high volume of exercise
visits at clinical settings required of patients over an
extended period of time.
Walking programs that occur in community settings,
deﬁned as those programs outside of supervised hospital
and clinical settings, have recently gained attention in the
vascular medicine literature because they potentially bypass
many of the barriers associated with supervised walking
programs. However, given that community walking
programs have largely been ineffective for PAD patients,
a discussion of the various methods used and relevant
outcomes assessed after walking interventions may help
reveal why this type of therapy has been ineffective. Thus,
the purpose of this review was to summarize the methods
and results of community walking programs for PAD
patients with IC.
Relevant outcomes for PAD. Treadmill walking is
a primary objective modality to assess a PAD patient’s
walking ability and is considered reliable and valid for those
with IC.2,3 The most commonly assessed treadmill
outcomes include measures of claudication onset time
(COT) or distance walked to claudication onset and peak
walking time (PWT) or maximal walking distance.4,5
Typically COT and PWT are assessed using a graded
treadmill protocol,6 but constant load treadmill testing6,7 is
also an accepted method used to assess walking distance.
The functional ability of PAD patients relates to their
physical ability to perform sustained ambulation at home
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activities that involve the lower limbs (eg, moving from
a seated to standing position). This is an important
outcome to evaluate because PAD patients demonstrate
a greater functional decline over time than those without
PAD.8 Objective measures, such as the 6-minute walk
test, as well as balance and short-distance shuttle tests
(walking a deﬁned distance back and forth signaled by
a timer), have been used to assess functional ability.9-13
The 6-minute walk test (walking a predeﬁned course
for a speciﬁed time and recording the distance achieved)
is perhaps the best and most valid physical function test
for PAD and IC.11-13 Several trials have demonstrated
that meters walked over the 6 minutes increase signiﬁcantly
after exercise interventions for PAD.14-16 This is an impor-
tant outcome, because the 6-minute walk test is strongly
related to mortality rates, mobility, and overall physical
function during daily life in PAD patients.12,17 Thus, func-
tional outcomes provide clinicians with additional objective
information for evaluating the progress of the patient after
a therapeutic intervention, given that these tests reﬂect the
patient’s walking ability from a practical standpoint.
Patient-reported outcomes, deﬁned as a patient’s
perceived physical, emotional, and social well-being and
function, are also important to assess because a patient’s
perception of a treatment’s effect on his or her health
may aid a clinician in determining the appropriate therapy
for PAD.18 A number of validated general and PAD-
speciﬁc tools exist for measuring patient-reported
outcomes after exercise training programs, the most
commonly used being the Medical Outcomes Study
Short-Form 36-item questionnaire and the Walking
Impairment Questionnaire.19-21 Other validated disease-
speciﬁc questionnaires that have been used in PAD patients
with IC include the Peripheral Artery Questionnaire,22
Vascular Quality of Life questionnaire,23 the Claudication
Scale,24 and the Intermittent Claudication
Questionnaire.25
Supervised walking exercise: Cornerstone of PAD
therapy. A number of supervised exercise modalities, such
as leg and arm ergometry, pole striding, and strength
training, have been used to treat PAD and IC in supervised
clinical exercise settings.26 However, the primary validated
exercise therapy for patients with PAD and IC is a program
of hospital-based supervised walking.27,28 This therapy is
recommended as an initial treatment for IC before any
endovascular or open revascularization and is classiﬁed IA
by the American College of Cardiology (ACC)/American
Heart Association (AHA) PAD practice guidelines.27 This
rating is given because of the pronounced improvement in
walking ability of PAD patients with IC after the therapy,
as demonstrated in multiple randomized clinical trials.29-32
Supervised walking exercise has also been cited in trials to
be a beneﬁcial treatment after endovascular or surgical
procedures, providing additional evidence of its beneﬁt for
PAD patients.33,34
Effects of supervised walking for PAD patients.
Supervised walking programs consist primarily of treadmillwalking exercise and include brief periods of rest when
moderate leg pain occurs.32 Supervised walking exercise
has been studied extensively, and the results of most
randomized clinical trials indicate that this therapy
improves the overall walking ability of PAD
patients.29,30,35,36 In addition, a Cochrane database
systematic review of randomized controlled trials con-
ducted by Watson et al37 found that PWT (or maximal
meters walked) and COT (or distance to claudication
onset) are signiﬁcantly improved after exercise training
compared with the standard of care or placebo for PAD
patients with IC. Brieﬂy, in a sample of 255 PAD patients
in seven total studies, the Cochrane review found a PWT
mean difference of 5.12 minutes between supervised
walking compared with standard of care and placebo
groups.37 Similar results were demonstrated for 391 PAD
patients in six total studies, where a mean difference of
113.2 m was found between supervised walking and stan-
dard of care or placebo groups (P < .001). The COT was
also improved for patients in the supervised walking vs
standard of care or placebo groups in nine total studies
analyzed.
The exact physiologic changes leading to the improve-
ment of walking ability in PAD patients remain unclear.
Several PAD studies have reported that the beneﬁt ob-
tained from walking exercise may be due to an improve-
ment in skeletal muscle adaptation and metabolism as
well as in the oxidative capacity of the active muscles.38,39
A number of studies have shown that exercise rehabilitation
for IC does not improve blood ﬂow to the leg,40,41
although several studies have reported modest improve-
ments.30,42 Other possible mechanisms for the improve-
ment in walking ability include an improvement in
walking economy (rate of oxygen consumption in relation
to distance completed),43,44 increased angiogenesis,45
a decrease in blood viscosity,46 improvement in endothelial
function,47 a decrease in atherosclerosis, and an increase in
pain tolerance.30
Supervised walking exercise prescription. The stan-
dardized nature of the supervised walking program design
has been highlighted as one of its strengths.1 Supervised
exercise training is effective in part because of a prescribed
exercise intensity, frequency, and duration that induce
a training response in PAD patients with IC. Typically, the
walking program lasts for a minimum of 30 to 45 minutes
each session, for at least three sessions per week, and
a minimum of 3 months.27 Regarding exercise intensity,
walking to moderate (not mild or severe) levels of pain on
a treadmill before resting is prescribed most commonly and
is also recommended by the ACC/AHA PAD practice
guidelines.27 Thus, the patient walks until the onset of
moderate leg pain, rests until the pain has subsided, and
then resumes walking again.
It is important to note that PAD patients may experi-
ence a familiarization effect during repeated exercise testing
or training on a treadmill that is not solely related to
a walking intervention.5 Clinicians and researchers should
be aware of this when establishing the efﬁcacy of the walking
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familiarization with the treadmill may be due to biomechan-
ical improvements in walking as patients become familiar
with the treadmill, which has been cited to be as high as
100% improvement over just several weeks.5
The role of the different exercise prescription compo-
nents (eg, frequency, duration of exercise, and intensity of
walking) and assessing which contributes most to the
training response is unclear. A recent systematic review of
25 randomized clinical trials used regression analyses to
evaluate the effect of individual supervised walking exercise
prescription components on maximal walking distance and
distance to claudication onset in PAD patients.48 Results
indicated that none of the exercise prescription components
were independently associated with a signiﬁcant improve-
ment in maximal walking distance for PAD patients. The
authors did note that medium-length programs (ie, 12-
26weeks) weremore likely to show improvement in walking
outcomes than short-term (<12 weeks) and long-term
(>26 weeks) exercise programs (maximal walking dis-
tance: þ223 vs þ123 vs þ145 m; distance to claudication
onset: þ146 vs þ100 vs þ109 m).48 This ﬁnding however
conﬂicts with recent reports by Gardner et al,49 who deter-
mined that PWT and COT improve quickly during the ﬁrst
2 months of supervised walking and then plateau, in addi-
tion to implications that adherence to exercise is better
with programs that are only 2 months in duration. Until
more research in this area is conducted, the greatest
improvements in the walking ability of PAD patients occur
with a comprehensive exercise prescription strategy that
uses established exercise frequency, duration, and intensity
components, which has been the accepted practice during
the last several decades.32
Supervised walking is effective but not feasible.
Supervisedwalking exercise has been cited as cost-effective in
improvingwalking ability for patients with claudication.50-56
Brieﬂy, van Asselt et al53 evaluated the cost-effectiveness of
supervised walking compared with unsupervised walking
where only general walking advice was given. Findings
indicated that the supervised walking program was more
effective for improving maximal walking distance than the
unsupervised walking program for PAD patients (620 vs
400 m; P < .001) but was also more costly (V3407 vs
V2304), which may be a barrier to implementing super-
vised walking programs. In the United States, there is a lack
of insurance reimbursement for supervised walking
programs, few available local training centers, and PAD
patients are required to travel to available facilities several
days per week for several months, which may not be
feasible.57,58 Thus, supervised walking programs are effec-
tive, but the difﬁculty of implementing such programs
provides a rationale for the use of walking programs in
community settings because they may be less costly and
more feasible for patients to participate in. When consid-
ering the environment of the exercise sessions, many
barriers associated with supervised walking programs may
be bypassed when programs are conducted in community
settings.METHODS
We reviewed PubMed/MEDLINE and the Cochrane
database to ﬁnd studies that conducted community
walking exercise programs for PAD patients with IC from
1990 to 2013. Because of the multiple study designs for
walking programs in community settings for PAD, we
included a broad combination of search terms to identify
appropriate studies in the area. Search terms included
“community exercise,” “home exercise,” “unsupervised
exercise,” “physical activity,” “walking,” “peripheral artery
disease,” “peripheral arterial disease,” “PAD,” and “inter-
mittent claudication.” A large number of studies used
a treatment arm that only included general advice to
walk. We therefore narrowed our search further to include
only those studies that reported PWT or maximal walking
distance as a primary walking outcome. Fewer studies were
identiﬁed that included more intensive exercise program
components (eg, monitoring, feedback) for community
walking programs and PAD. Thus, we included all studies
in this area regardless of the design or study end points.
RESULTS
Community walking programs. Walking programs
for PAD patients in community settings can refer to any
form of structured ambulation program completed outside
a supervised clinical setting. Typically, these programs orig-
inally consisted solely of advice to walk in the community
(thus unsupervised), but more recent studies have provided
innovative components and approaches to improve overall
delivery. The current recommendation and level of evi-
dence for community walking programs (unsupervised),
as reported in the ACC/AHA PAD practice guidelines
for the management of patients with PAD, is class IIb,
with an evidence level of B,27 indicating that these
programs are not well established as an effective treatment
option. Findings from multiple trials of supervised exercise
vs nonsupervised exercise programs for patients with PAD
and IC support the ACC/AHA ratings.
In addition, a Cochrane database systematic review
examined walking outcomes after supervised exercise
therapy vs nonsupervised (home and community) exercise
therapy for IC.59 Maximal walking distance was greater
for supervised walking groups than for the nonsupervised
groups after outcome assessment intervals of 3 months
(236 patients in six studies; overall effect size [magnitude
of treatment effect]: 0.58; 95% conﬁdence interval [CI],
0.31-0.85; P < .0001), 6 months (172 patients in ﬁve
studies; overall effect size: 0.89; 95% CI, 0.57-1.21; P <
.0001), and 12 months (69 patients in two studies; overall
effect size: 1.01; 95% CI, 0.50-1.52; P < .0001).
Results of PAD community walking studies with
advice only. Many of the community walking programs
for PAD and IC to date have been conducted with advice
to walk but with little further instruction, thus relying
primarily on patient self-monitoring.30,36,57,60-69 Regen-
steiner et al36 randomly assigned PAD patients to a super-
vised hospital-based walking program or an unsupervised
Table I. Randomized controlled trials primarily using exercise advice in community walking programs for peripheral
artery disease (PAD) patients
First author
(year) Sample sizea Study lengthb Other interventions
Community walking
program description Performance outcomes
Hiatt30
(1990)
19 12 weeks Supervised walking Control group given
instructions to continue usual
activity and no regular
exercise.
PWT increased 7.5 minutes in
supervised group and
improved to greater degree
than control group PWT
(þ1.1 min; P < .05)
Regensteiner36
(1997)
20 12 weeks Supervised walking Fast walking 3 d/wk; walk/rest
for 35-50 minutes to
moderate pain and weekly
support calls from staff.
Supervised walking improved
PWT (þ137%) compared
with unsupervised
community walking (þ5%;
P < .05).
Patterson63
(1997)
47 12 weeks Supervised walking Walking advice (3 times weekly,
20-40 minutes); weekly
education lectures;
completed exercise logs.
PWT and COT improved more
in supervised (þ207%
and þ337%) than home
exercise (þ70% and þ131%,
P < .05) groups.
Delis64
(2000)
37 4.5 months Combined IPC with
instructions to walk
and 75 mg/d aspirin
Instructed to walk at least 1 h/
d and given 75 mg/d aspirin.
Median PWD and COD
improved in the combined
group compared with the
unsupervised home group
(P < .05).
Savage66
(2001)
21 12 weeks Supervised walking Advice to walk to maximal pain
and rest (15 minutes total
walking) 3 times/wk;
contacted monthly by staff
for support.
PWD change scores statistically
similar for patients in
supervised walking and advice
to walk groups (þ311.8
vs þ204.2 m; P > .05).
Degischer62
(2002)
59 12 weeks Supervised walking;
combined supervised
walking and
clopidogrel
Upfront advice for walking
exercise (1 h/d on track);
walk until 60% pain level, rest,
resume upon cessation of
pain.
Improvements in PWD for
supervised walking and
combined group
(þ83%; þ131%; P < .05); no
signiﬁcant change in PWD
for walking advice group
pre/post (þ5.4%).
Cheetham61
(2004)
56 12 weeks Supervised walking General advice to walk (3
times/wk, 30 min/session);
advice for stair climbing and
tiptoe walking.
Supervised walking improved
PWD (þ129%) compared
with the advice group (þ69%;
P ¼ .001).
Kakkos60
(2005)
26 12 weeks Supervised walking;
IPC
Patients instructed to walk daily
to near maximal pain, for at
least 45 minutes.
No signiﬁcant change in
walking advice group for
median PWD (þ5 m) or
median COD (þ0 m).
Parr67
(2009)
25 6 weeks Supervised aerobic
exercisec; supervised
strength training
Patients advised to “walk as
much as possible at home.”
PWD higher for aerobic
exercise group than for
strength training and walking
advice groups (þ93.9%
vs þ7.3% vs þ7.0%; P < .01).
Allen69
(2010)
33 12 weeks Supervised walking Walked at home 3 times/wk for
30 minutes and recorded
activity (phone call once
every 3 weeks).
No signiﬁcant change in PWT
or COT for home walking
group (þ93; þ77 seconds).
Nicolai57
(2010)
252 52 weeks Supervised walking;
supervised walking
with feedback
Walking advice and exercise
brochure provided; instructed
to complete 3 sessions/d to
maximal pain.
Differences in PWD for advice
group vs supervised walking
and supervised walking with
feedback groups (110 vs 310
vs 360 m; P < .001).
COD, Claudication onset distance; COT, claudication onset time; IPC, intermittent pneumatic compression; PWD, peak walking distance; PWT, peak walking
time.
aTotal sample size for patients who completed the study.
bStudy length for intervention time period.
cForty-ﬁve minutes of walking, cycling, circuit training, and stretching.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 6 Mays et al 1681
Table II. Review of trials using more intensive community walking programs to treat patients with peripheral artery
disease (PAD)
First author
(year)
Study design, other
interventions (sample
sizea; study lengthb) Community walking program description Performance outcomes
Wullink83
(2001)
Nonrandomized, single
group (n ¼ 24; 24 weeks)
Instructed to walk 3 times/d and 3 times/
wk at self-selected speed until near
maximal pain then rested. Recorded
walking sessions in a diary. HCM
model86 used and patients met staff every
3 weeks.
COD improved (þ58 m; P < .05) but no
signiﬁcant changes in PWD (þ54 m). No
signiﬁcant changes in WIQ distance
(þ3.0%), speed (þ3.2%), or stair
climbing (þ1.5%) scores.
Roberts68
(2008)
Prospective cohort, no control
(n ¼ 47; 12 weeks)
Advice given to walk at least 1 h/d with
rest periods. Patients contacted by phone
weekly for support and also completed
exercise logs.
Increase in PWD between baseline and
12 weeks (þ76.2%; P < .001). The
VascuQOL total score improved
(þ22.4%; P < .001).
Manfredini80
(2008)
Nonrandomized, walk advice,
Ti-E (n ¼ 126; 6 months)
Patients in the Ti-To group completed
walking at home consisting of 1 minute
each of walk/rest, twice daily, 6 d/wk
for 10 minutes each session, at MAS
(metronome used to maintain speed,
chair used during rest). Patients
completed walking diary and family or
caregiver ensured diary completion.
Signiﬁcant intragroup change scores for
COD and PWD in Ti-To (þ51
and þ83 m; P < .0001) and Ti-E (þ27
and þ44 m; P < .0001) groups.
Signiﬁcant differences between groups
for walking outcomes at 6 months
(COD: P ¼ .001; PWD: P ¼ .0001).c
Mouser82
(2009)
Retrospective, no control
(n ¼ 41; 6 months)
Exercise physiologist provided upfront
advice for home walking program
(30 min of walking 3-5 d/wk to near
maximal pain, followed by rest until pain
resolved, walking resumed). Also
completed walking log and were given
feedback at least every 2 months.
Patients demonstrated a signiﬁcant increase
from baseline to follow-up for COD
(103.0 to 192.0 m; P ¼ .001) and PWD
(400.9 to 480.1 m; P ¼ .006).d
Collins79
(2011)
RCT, control group
(n ¼ 145; 6 months)
Upfront education sessions targeting
readiness to engage in walking (modiﬁed
PACE protocol87). Patients completed
two 1-hour walking sessions with staff
(eg, at hospital or park), were
encouraged to walk with staff and other
patients 1 d/wk and minimum 3 d/wk
unsupervised for 50 min/session with
pedometers and received biweekly calls
from staff.
The primary outcome of PWD was similar
between groups (24.5 vs 39.2 m).
Walking speed assessed by the WIQ
increased signiﬁcantly in the intervention
(þ5.7% 6 2.2%) vs control group
(1.9% 6 2.8%; P < .05). Signiﬁcant
differences in the mental health
component score of the SF-36 between
intervention (þ3.2%6 1.5%) and control
(2.4% 6 1.5%; P < .05) group.
Gardner44
(2011)
RCT, supervised walking
group and control
group (n ¼ 92; 3 months)
Community program similar to supervised
walking (walking to near maximal IC,
3 d/wk, 20-minute sessions progressing
to 45 minutes). Patients completed
exercise logs and wore activity monitors
during walking and participated in seven
15-minute feedback sessions with staff
(discussed progress and new goals).
PWT and COT higher in supervised
(þ215; þ165 seconds) and community
(þ124; þ134 seconds) groups than in
the control group (10; 16 seconds;
P < .05). Community group improved
WIQ distance (þ10%), speed (þ11%),
and stair climbing (þ10%) scores (P <
.05) and the SF-36 physical function
score (þ8%; P < .01).
Hiatt85
(2011)
RCT, combined PLC and
home walking group
(n ¼ 59; 6 months)
2 weeks of initial supervised walking,
monthly thereafter. Patients instructed to
walk at home for 50 minutes, 3 d/wk to
moderate leg pain in 3-5 minutes,
followed by rest. Completed walking
diaries and wore an activity monitor for
each session.
No signiﬁcant differences in changes scores
for PWT or COT between home walking
group (PWT: þ218 6 367 seconds;
COT: þ100 6 100 seconds) and
combined group (PWT: þ266 6
243 seconds; COT: 1746 183 seconds).
WIQ and SF-36 scores improved for
both groups but were not different from
each other after 6 months.
Fakhry81
(2011)
Longitudinal cohort,
supervised walking
group (n ¼ 95; 24 weeks)
Patients enrolled in the home walking
group were given an information sheet
and advice to walk daily for 30 minutes
to near maximal pain and 1 minute
walking at slower pace until pain
resolved. Patients also completed three
interim evaluations of walking distance as
well as three 1-hour individual
counseling sessions with staff.
Adjusted mean differences were
demonstrated between the supervised
and home walking groups for PWD
(361%) and COT (953%). No differences
between groups for VascuQOL,
EuroQOL, and SF-36 scores measured at
24 weeks.
(Continued on next page)
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Table II. Continued.
First author
(year)
Study design, other
interventions (sample
sizea; study lengthb) Community walking program description Performance outcomes
McDermott14
(2013)
RCT, control group
(n ¼ 194; 6 months)
Home-based program consisting of goal
setting and a cognitive behavioral
walking intervention. Included weekly
group discussions with trained facilitator
(45 minutes) and walking on an indoor
track (45 minutes). Patients instructed to
walk “over ground” rather than on
treadmill.
6-minute walk distance improved
signiﬁcantly in the intervention group
compared with controls (357.4 to 399.8
vs 353.3 to 342.2 m; P < .001). PWT
changes scores were also higher for
intervention than for controls
(þ1.01 min; P < .05).
COD, Claudication onset distance; COT, claudication onset time; EuroQOL, European Quality of Life questionnaire; HCM, Health Counseling Model; IC,
intermittent claudication; MAS, maximal asymptomatic speed; PACE, Patient-centered Assessment and Counseling for Exercise; PAD, peripheral arterial
disease; PLC, propionyl-L-carnitine; PWD, peak walking distance; PWT, peak walking time; RCT, randomized controlled trial; SF-36, Short Form 36-item
questionnaire; Ti-E, traditional home-based free walking program; Ti-To, test in-train out walking program; VascuQOL, Vascular Quality of Life question-
naire; WIQ, Walking Impairment Questionnaire.
aTotal sample size for patients who completed the study.
bStudy length for intervention time period.
cA retrospective analysis was conducted by Malagoni56 evaluating the “test in-train out” program on patient-reported outcomes during a 2-year period in
patients with PAD and intermittent claudication (IC).
dPatient-reported outcomes were not examined in this trial.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 6 Mays et al 1683walking program in the community setting for a 3-month
intervention. Patients in the unsupervised community
walking program were given detailed exercise instructions
during the initial hospital visit, followed by a weekly phone
call, but did not receive any direct training. The main
ﬁnding was that patients randomized to the supervised
walking program improved treadmill exercise performance
(PWT: þ137%; COT: þ150%) more than the unsupervised
walking program participants in the community setting
(PWT: þ5%; COT: þ26%).
Recently, Allen et al69 examined walking outcomes of
PWT and COT in 33 PAD patients with IC after a 3-
month period. Patients were randomized to supervised
walking exercise in a hospital setting (intervention) or
unsupervised walking at home (control). The unsupervised
home program consisted of advice to exercise daily by
walking, and patients were asked to keep notes of their
exercise and were also called every 3 weeks to answer any
exercise-related questions the patients had. The supervised
walking group improved PWT and COT from baseline to
3 months (PWT: þ260 seconds; COT: þ138 seconds),
whereas the unsupervised home walking group did not
signiﬁcantly improve either walking outcome from baseline
to 3 months (PWT: þ93 seconds; COT: þ77 seconds).
Table I provides a review of randomized controlled
PAD exercise trials using the community as the setting
for walking where primarily exercise advice was given.
Eleven studies that included 595 PAD patients (sample
size range, 19-252 patients) were identiﬁed that evaluated
walking outcomes of PWT or maximal walking distance as
well as COT or distance to claudication onset. Four of the
11 studies reported PWT as the primary walking out-
come, whereas the other seven evaluated maximal walking
distance. Results overall supported that supervised exer-
cise improved walking more than home programs. Manyof these programs used the community walking groups
as the control arm (standard of care), given that many
patients with PAD have not habitually exercised, and
often, the primary aims were to establish the effectiveness
of supervised walking exercise. Most of these programs
have not yielded signiﬁcant improvement in PAD
patients’ walking ability.
New perspectives for PAD walking programs in
community settings. More recently, programs are being
developed using established supervised walking exercise
guidelines that more intensively train and monitor PAD
patients over the course of an intervention and provide
direct feedback on how to improve walking ability. In
contrast to supervised walking exercise programs, less is
known about the optimal prescription for PAD patients
walking in the community given that barriers and facilita-
tors to exercise are different between settings. Because
supervised exercise training is efﬁcacious, modeling the
community program on some elements of the supervised
program may be beneﬁcial. However, a limiting factor of
community walking program implementation is that the
guidelines for supervised exercise training overall may not
be feasibly applied in the typical community setting. For
example, a patient who experiences IC in the community
while walking may stand in place rather than sit because
adequate seating may not be available. Thus, patients
with PAD have cited the need to take rest breaks as a key
barrier and that the availability of seating for rest facilitates
walking in community settings.70
An additional impedance to walking exercise in
community settings (outdoors speciﬁcally) cited by PAD
patients in focus groups is the quality of sidewalks. Uneven
or icy sidewalks were discouraging to patients and led to
decreased ambulation. Environmental factors relating to
low-quality walking surfaces have also been cited as
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adults, with 73% of falls directly resulting from uneven side-
walk surfaces and due to objects such as curbs.71 Thus, the
walking environment could potentially present numerous
barriers to implementing effective programs in community
settings for PAD patients, with barriers varying for each
individual and highly speciﬁc to their disease-related
impairments.72-74 Given this constraint, it may be impor-
tant that interventions based in the community include
an evaluation of objective features of the local walking envi-
ronment to help PAD patients develop a tailored walking
plan to improve adoption and adherence to exercise in
the community setting.
The question of how the elements of supervised exer-
cise programs can be implemented into the community
setting is critically important and requires additional atten-
tion for these programs to be successful. Thus, the failure
of community exercise training studies that have only
provided advice to walk at home demonstrates the lack of
acknowledgment of the multifaceted social and environ-
mental landscape that is associated with community
walking.
Although it has been previously understood that exer-
cise programs should ideally incorporate a sufﬁcient level of
intensity, duration, and frequency to be effective,32 recent
evidence indicates prescription components that include
low-intensity exercise may be just as beneﬁcial as high-
intensity walking.75-77 This is important to acknowledge,
because PAD patients are generally sedentary,78 may not
be aware of the appropriate exercise regimen required to
improve their walking ability, and are thus noncompliant
at higher levels of walking intensity.
Another important factor is that a program of exercise
training initially may provide the knowledge and skills
necessary to increase a patient’s propensity to walk.
However, if travel to clinical settings for supervised walking
is not feasible even for a short interval (1-2 weeks),
community locations may need to be selected to
adequately train PAD patients on how to walk effectively.
Results of recent approaches to PAD community
walking programs. Recent studies of community walking
have provided clinicians and researchers further direction
on how to successfully use supervised walking program
components in an effort to translate the success of super-
vised programs to community settings.44,56,79-84 Evidence
suggests that this type of intervention yields better results
than studies where little or no exercise instruction is given
to patients. Gardner et al44 randomized 119 patients with
IC into a supervised walking program, a walking program
in the community setting, and a nonexercising control
group. Patients in the walking groups were (1) provided
activity monitors, (2) received seven 15-minute sessions
where they discussed their progress with an exercise phys-
iologist, (3) were given feedback about the data from the
activity monitor, and (4) were given new instructions on
changes in exercise duration. Differences were found
between both exercise groups vs the control group for
walking outcomes of PWT and COT (supervised walking:PWT þ215 and COT þ165 seconds; community walking:
PWT þ124 and COT þ134 seconds; control group:
PWT 10 and COT 16 seconds; P < .05).44
A multicenter, randomized control trial conducted by
Hiatt et al85 found that the inclusion of supervised walking
at set intervals in addition to using an activity monitor and
exercise log book during a 6-month community walking
program was beneﬁcial for PAD patients. The authors
concluded that exercise was as effective for improving
walking outcomes and patient-reported outcomes (via the
Walking Impairment Questionnaire and Short-Form 36-
item questionnaire) compared with exercise combined
with the medication propionyl-L-carnitine. Thus, commu-
nity programs with more intensive individual interventions
modeled after supervised walking programs provide
evidence of effectiveness for improving walking ability
and patient-reported outcomes.
Recently, McDermott et al14 conducted a randomized
controlled walking trial for PAD patients with and without
IC using a group-mediated cognitive behavioral walking
intervention that included principles from social cognitive
theory, group dynamics, and the self-regulation knowledge
base. Control patients attended weekly (60-minute) health
education group sessions and lectures for the management
of health (eg, hypertension control, cancer screenings).
Patients in the intervention group attended once-weekly
group meetings for a total of 90 minutes, consisting of
45 minutes of education lectures and counseling (eg, bene-
ﬁts of walking, self-monitoring) and 45 minutes of walking
in a supervised setting at an indoor track. Patients were
then instructed to walk to severe leg discomfort in the
community (outside, over ground rather than indoors on
the treadmill) during the course of the 6-month interven-
tion for a minimum of 5 days per week and up to
50 minutes each session. Results indicated that the primary
outcome of change in 6-minute walk distance was signiﬁ-
cantly different for patients in the intervention group
(þ42.4 m; 95% CI, 27.9-56.8 m) compared with patients
in the control group (11.4 m; 95% CI, 25.4 to
3.2 m; P < .001). Secondary outcomes of PWT and
COT were also signiﬁcantly different between intervention
(þ1.54 vs þ0.53 minutes; P ¼ .04) and control (þ1.43
vs þ0.42 minutes; P ¼ .02) groups.
Thus, the use of appropriate training advice to walk in
community settings, the inclusion of exercise supervision
at predeﬁned locations, and implementation of exercise
and health education for PAD patients in group settings
may be beneﬁcial for use in the development of comprehen-
sive community-based walking programs. Table II provides
a review of community walking trials that have provided
more intensive programming for patients with PAD and
IC. In total, nine trials comprising 823 PAD patients were
reviewed, which included three studies that did not have
a comparison group or were retrospective by design. Three
trials evaluated PWT and COT, and the other six examined
maximal walking distance and distance to claudication onset
in PAD patients after the exercise programs. Not all studies
have been successful for improving outcomes in PAD
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results.79,83 In general, however, most of these types of
studies did report improvements in walking ability and
questionnaire-based outcomes for PAD patients.
CONCLUSIONS
This review provides an overview of the beneﬁts of
walking exercise and a discussion of community walking
programs to improve the health of PAD patients. Super-
vised walking exercise improves the walking ability, func-
tional ability, and patient-reported outcomes of PAD
patients. However, because the current state of the health
care system limits the supervised exercise treatment options
for PAD patients in addition to other logistical barriers (eg,
transportation, proximity to clinics), it is clear that innova-
tive community walking programs need to be developed.
Community programs have the potential to be success-
ful because they are generally more convenient for the
patient’s schedule; that is, patients are able to exercise at
locations close to their homes and avoid potential barriers
such as transportation to supervised exercise in clinics.
Inclusion of some elements of supervised training may be
needed for exercise programs that primarily occur in
community settings as a way of coaching PAD patients
who have never exercised consistently. Thus, future studies
aimed at improving on the “go home and walk” exercise
advice strategy often provided to PAD patients should
incorporate more intensive monitoring by staff and coach-
ing patients to monitor their own exercise while in the
community. Community walking programs for symptom-
atic PAD may be effective when a proper intervention is
used because the characteristics of the intervention need
to go beyond simple recommendations to exercise. The
implications of successful programs include the improve-
ment of PAD patients’ walking ability, enhanced functional
ability in community settings, an improved overall quality
of life, and a potential decrease in health care expenditures.AUTHOR CONTRIBUTIONS
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